#### Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 4

#### VALEANT PHARMACEUTICALS INTERNATIONAL

Form 4 June 29, 2005

### FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

30(h) of the Investment Company Act of 1940

**OMB** Number:

**OMB APPROVAL** 

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

obligations

may continue.

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

See Instruction 1(b).

(Print or Type Responses)

	Address of Reporting I	NDER Symbol VALE	er Name <b>and</b> Ticker or Tradi ANT PHARMACEUTI RNATIONAL [VRX]	Issuer	5. Relationship of Reporting Person(s) to Issuer  (Check all applicable)			
(Last) 3300 HYLA	(First) (MAND AVENUE		of Earliest Transaction Day/Year) 2005	_X_ Direct Officer below)	or 10% Owner (give title Other (specify below)			
COSTA ME	(Street) ESA, CA 92626		nendment, Date Original onth/Day/Year)	Applicable Li _X_ Form file Form file	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person			
(City)	(State)	(Zip) Tak	ole I - Non-Derivative Secur		sed of, or Beneficially Owned			
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 3, 4 and	d of (D) Securities 5) Beneficially Owned Following Reported Transaction (Instr. 3 and	Form: Direct Indirect (D) or Beneficial Indirect (I) Ownership (Instr. 4) (Instr. 4)			
Phantom stock	06/28/2005		A 84 (1) A	\$ 22,868	D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of **SEC 1474** information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

#### Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5.  onNumber of Derivative Securities Acquired (A) or Disposed of (D)		ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	of ng s	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
				Code V	(Instr. 3, 4, and 5)  (A) (D)	Date Exercisable	Expiration Date	or Title Nu of	umber		

# **Reporting Owners**

Reporting Owner Name / Address

Director 10% Owner Officer Other

INGRAM ROBERT ALEXANDER
3300 HYLAND AVENUE X

COSTA MESA, CA 92626

## **Signatures**

By: Pamela Chronister Lewis For: Robert A.

Ingram

06/29/2005

\*\*Signature of Reporting Person Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents phantom stock in lieu of cash for Board and Committee meeting fees, pursuant to the election of the Board member, which may be settled only in common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2